Clinical Trial Update: A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical study of SHP674 (Pegaspargase) in newly diagnosed, untreated acute lymphoblastic leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• SHP674 (pegaspargase)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2022-06-10